Last Updated on July 11, 2021 by The Health Master
Mankind Pharma said it has received the licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of C-19. 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior.
The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy’s Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe C-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised C-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the C-19 patients, it added.
‘Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic,’ the company said.
40 Pharma Firms showed interest in anti Covid drug: DRDO
DRDO develops C-19 Antibody detection kit
CDSCO asks Philips India to discontinue these Ventilators
IPCA Lab gets CDSCO nod to conduct Phase-III study of HCQ
Mankind gets CDSCO nod for phase-I trial of Anti Diabetic drug
IPC and CDSCO meet to outline plan for designing Pharmacovigilance cell
All Legislation of India (for Pharma and Health professionals)
Latest Notifications: General (Pharmaceuticals)
Starch powder sold as Black Fungus medicine: Scam busted
Fake Favipiravir racket busted: FIR lodged
Delhi High Court set up IPD for Pharma Industry
ER for D Pharmacy is a step in right direction: Pharmacy…
For informative videos by The Health Master, click on the below YouTube icon: